Non-Small Cell Lung Cancer (NSCLC) Market Report 2026

Non-Small Cell Lung Cancer (NSCLC) Market Overview

• Non-Small Cell Lung Cancer (NSCLC) market size has reached to $42.2 billion in 2025 • Expected to grow to $70.81 billion in 2030 at a compound annual growth rate (CAGR) of 11% • Growth Driver: Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market • Market Trend: FDA Accelerated Approval For Targeted Therapies Enhances Treatment Options In Non-Small Cell Lung Cancer (NSCLC) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Small Cell Lung Cancer (NSCLC) Market?

Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in the tissues of the lungs and is characterized by the abnormal growth of cells. It is primarily caused by long-term smoking, genetic mutations, air pollution, and secondhand smoke. The main types of non-small cell lung cancer (NSCLC) are squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma is a type of cancer that arises from the squamous epithelial cells and can occur in other areas of the body. The various types of therapies are included, such as radiotherapy, laser therapy, photodynamic therapy (PDT), and others, with various distribution channels involved, including hospital pharmacies, online pharmacies, and others.

What Is The Non-Small Cell Lung Cancer (NSCLC) Market Growth Forecast?

The non-small cell lung cancer (nsclc) market size is expected to see rapid growth in the next few years. It will grow to $70.81 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to rising adoption of targeted therapies and immunotherapy, increasing investment in lung cancer diagnostics, growth of personalized medicine, expansion of oncology centers and specialty clinics, development of ai-based predictive models and imaging solutions. Major trends in the forecast period include rising adoption of targeted therapy and immunotherapy, increasing use of advanced radiotherapy techniques, growing implementation of laser therapy and photodynamic therapy, expanding deployment of early diagnosis and screening programs, advancing integration of ai-powered imaging and predictive oncology.

Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types 2) By Therapy: Radiotherapy, Laser Therapy, Photodynamic Therapy (PDT), Other Therapies 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels Subsegments: 1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma 2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma 3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma 4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma

What Is The Driver Of The Non-Small Cell Lung Cancer (NSCLC) Market?

The increasing rate of tobacco consumption is expected to propel the growth of the non-small cell lung cancer (NSCLC) market going forward. Tobacco consumption refers to the use of tobacco products by individuals, typically in the form of smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains several carcinogens that can damage the DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small-cell lung cancer (NSCLC). For instance, in October 2024, according to the 2024 National Youth Tobacco Survey published by US Food and Drug Administration (USFDA), a US-based federal agency, 1.1% of all students (approximately 2.25 million) reported current use of tobacco products, with 10.1% of high school students (about 1.58 million) and 5.4% of middle school students (around 640,000) using tobacco; additionally, 2.8% of students (about 760,000) reported current use of any combustible tobacco product, while 3.0% (approximately 840,000) reported using multiple tobacco products. Therefore, the increasing rate of tobacco consumption is driving the growth of the non-small cell lung cancer (NSCLC) industry.

Key Players In The Global Non-Small Cell Lung Cancer (NSCLC) Market

Major companies operating in the non-small cell lung cancer (nsclc) market are Pfizer Inc., F. Hoffmann‑La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Clovis Oncology, Revolution Medicines, Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company Limited, BeiGene Ltd., DualityBio, Gilead Sciences Inc., Mirati Therapeutics Inc., Arcus Biosciences Inc., NeoImmuneTech

Global Non-Small Cell Lung Cancer (NSCLC) Market Trends and Insights

Major companies operating in the non-small cell lung cancer market are focusing on developing targeted therapies, such as FDA accelerated approval for drugs targeting specific genetic mutations, to enhance treatment options for patients. FDA accelerated approval refers to a regulatory pathway in which the U.S. Food and Drug Administration (FDA) grants earlier approval to a therapy that specifically targets a molecular or genetic abnormality in a disease, based on surrogate or intermediate clinical endpoints reasonably likely to predict clinical benefit. For instance, in July 2025, Dizal (Jiangsu) Pharmaceutical Co., Ltd., a China-based research-based biotechnology company, launched sunvozertinib (Zegfrovy) for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Zegfrovy is administered orally at 200 mg once daily with food until disease progression or unacceptable toxicity. The therapy demonstrated a confirmed overall response rate of 46% and a duration of response of 11.1 months in the WU-KONG1B trial. The FDA approval also included the Oncomine Dx Express Test as a companion diagnostic to detect eligible patients. Sunvozertinib carries warnings for interstitial lung disease, gastrointestinal and dermatologic reactions, ocular toxicity, and embryo-fetal toxicity, reflecting its comprehensive safety profile.

What Are Latest Mergers And Acquisitions In The Non-Small Cell Lung Cancer (NSCLC) Market?

In December 2023, Pfizer Inc., a US-based biopharmaceutical company providing innovative medicines including small molecules, biologics, and immunotherapies, acquired Seagen for approximately US$43 billion. Through this acquisition, Pfizer aims to strengthen its oncology pipeline, particularly in Non-Small Cell Lung Cancer, by leveraging Seagen’s world-leading antibody-drug conjugate (ADC) technology to develop next-generation cancer therapies. Seagen is a US-based biotechnology company that is actively developing and studying therapies for NSCLC.

Regional Outlook

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Small Cell Lung Cancer (NSCLC) Market?

The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Small Cell Lung Cancer (NSCLC) Market Report 2026?

The non-small cell lung cancer (nsclc) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (nsclc) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.